NCT02891954View on ClinicalTrials.gov

Genetics of Response to Canagliflozin

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 25, 2023

Study Completion Date

September 25, 2025

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Canagliflozin

Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Maryland, Baltimore

OTHER